New B7 Family Checkpoints in Human Cancers.
New B7 Family Checkpoints in Human Cancers.
复制标题
人类癌症中新的 B7 家族检查点。
DOI：
10.1158/1535-7163.mct-16-0761
复制
发表时间：
2017-07
影响因子：
5.7
通讯作者：
Dong C
中科院分区：
文献类型：
--
作者：
Ni L;Dong C
T细胞是抗肿瘤免疫反应中的主要效应细胞。T细胞的活化由先天免疫系统通过正性和负性共刺激分子调节。靶向免疫检查点调节剂，如程序性细胞死亡1（PD-1）/PD-1配体1（PD-L1）和细胞毒性T淋巴细胞抗原4（CTLA-4），在各种癌症中取得了显着的益处，这导致了针对其他相关B7/CD 28家族成员的抗体的多项临床试验。最近发现了5个新的B7家族配体B7-H3、B7-H4、B7-H5、B7-H6和B7-H7。在这里，我们回顾了最近对新的B7家族检查点分子的理解，因为它们已经来到癌症研究的前沿，肿瘤细胞利用它们来逃避免疫监视。本文的目的是解决新的B7家族分子的结构和表达，以及它们在控制和抑制T细胞以及NK细胞的免疫应答中的作用。我们还讨论了这些检查点表达在人类癌症中的临床意义和贡献。
T cells are the main effector cells in immune response against tumors. The activation of T cells is regulated by the innate immune system through positive and negative costimulatory molecules. Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefit in a variety of cancers, which leads to multiple clinical trials with antibodies targeting the other related B7/CD28 family members. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified. Here we review recent understanding of new B7 family checkpoint molecules since they have come to the front of cancer research with the concept that tumor cells exploit them to escape immune surveillance. The aim of this article is to address the structure and expression of the new B7 family molecules as well as their roles in controlling and suppressing immune responses of T cells as well as NK cells. We also discuss clinical significance and contribution of these checkpoint expressions in human cancers.